Breaking Research News from Breastcancer.org

Moderators

Combo of Tykerb, Herceptin, and Aromatase Inhibitor Seems Best for Metastatic, HER2-Positive, Hormone-Receptor-Positive Disease
January 12, 2018
The combination of Tykerb, Herceptin, and an aromatase inhibitor seems better than just Herceptin and an aromatase inhibitor or just Tykerb and an aromatase inhibitor for treating metastatic HER2-positive, hormone-receptor-positive breast cancer in postmenopausal women. Read more...

Moderators

Lynparza Approved to Treat Metastatic HER2-Negative Breast Cancer in Women With BRCA Mutations
January 12, 2018
On Jan. 12, 2018, the FDA approved Lynparza to treat metastatic HER2-negative breast cancer in women with a BRCA1 or BRCA2 mutation. Read more...

Moderators

Study Estimates Risk of Rare Cancer From Breast Implants
January 16, 2018
A Dutch study estimates that for every 7,000 women who get breast implants, one woman will develop anaplastic large-cell lymphoma in the breast by age 75. Read more...

seagan

Have we heard anything about whether MBCers with other, “BRCA-like" (DNA repair gene) mutations - such as CHEK2, which I have - will be eligible for Lynparza, if not now, soon?

I know of at least one clinical trial looking at another PARP inhibitor in non-BRCA, inherited mutations (a talazoparib trial at Stanford: https://clinicaltrials.gov/ct2/show/NCT02401347 - see cohort arm 2). But that's only at one location and requires measurable disease.

Would love to hear PARP inhibitors are becoming more accessible to those of us with non-BRCA mutations, either through trials or exceptions to narrowly approved drugs like this one.

Moderators

Hi Seagan, and thanks for posting. This thread is reserved for posting only Research News articles provided by Breastcancer.org, in an effort to get the breaking news to the Community, without diverting the conversation to other discussions about specific stories. If you'd like to further discuss an article here, we'd suggest going to the specific thread on this article: https://community.breastcancer.org/forum/8/topics/861743, or starting your own thread here in the Research News forum.

Thank you for understanding!

--The Mods

Moderators

Study Estimates Risks of Radiation Treatment for Breast Cancer in Women With Scleroderma
January 19, 2018
Research suggests that some women diagnosed with scleroderma and breast cancer treated with radiation had long-term skin tightening or thickening in the treatment area, but no disease flare-up. Read more...

Moderators

Two New Genetic Mutations Linked to Higher Risk of Breast Cancer
January 24, 2018
A study has found that mutations in the MSH6 and PMS2 genes are linked to higher-than-average breast cancer risk. Read more...

Moderators

Exercise Boosts Health of Breast Cancer Survivors
January 30, 2018
Regular exercise may increase the life expectancy of breast cancer survivors by lowering survivors' increased risk of heart disease and type 2 diabetes, along with recurrence. Read more...

Moderators

Program Can Help Ease Body Image Concerns and Improve Quality of Life
February 1, 2018
The Restoring Body Image After Cancer group therapy program, which uses guided imagery, seems to help improve body image as well as quality of life in women treated for breast cancer. Read more...

Moderators

Yet Another Biosimilar Seems as Safe and as Effective as Herceptin
February 2, 2018
SB3, a biosimilar to Herceptin, seems as effective and as safe as Herceptin. Read more...

Moderators

ASCO Releases Guidelines on Ways to Treat Sexual Problems in People With Cancer
February 9, 2018
The American Society of Clinical Oncology has issued new guidelines on ways doctors can help treat sexual problems in people diagnosed with cancer. Read more...

Moderators

Study Compares Four Genomic Tests for Breast Cancer
February 20, 2018
A study compared four genomic tests used to analyze early-stage, hormone-receptor-positive, HER2-negative breast cancer, but it's important to know the difference between prognostic and predictive tests when interpreting the results. Read more...

Moderators

FDA Authorizes 23andMe BRCA Genetic Test, but Test Only IDs Three Mutations
March 7, 2018
The FDA has authorized a direct-to-consumer test to identify BRCA mutations, but it's important to know that the test only looks for three mutations that are extremely rare in the general population. Read more...

Moderators

Most Newly Diagnosed Women Don't Receive Genetic Counseling, Even Though They Should Have It
March 16, 2018
Fewer than 50% of women newly diagnosed with breast cancer who should receive advice from a licensed genetic counselor actually get counseling. In addition, only about half of the women who should have genetic testing actually have that testing. Read more...

Moderators

New Guidelines Say Accelerated Whole-Breast Irradiation Should Be Used to Treat Most Breast Cancers
March 18, 2018
The updated guidelines say that most women diagnosed with breast cancer should be treated with accelerated whole-breast irradiation as the standard of care. Read more...

Moderators

Researchers Identify 110 Genes Associated With Breast Cancer
March 21, 2018
A research team has associated 110 genes with a higher risk of breast cancer using a new genetic analysis technique. Read more...

Moderators

Scalp Cooling Is Safe, Effective for Reducing Hair Loss Due to Chemotherapy, Study Finds
March 30, 2018
A retrospective study found that scalp cooling was effective and that the risk of scalp skin metastases was extremely low and should not interfere with the use of scalp cooling. Read more...

swimjames

Please let me know if you know anything about below research for recurrences:

Another very interesting area my RO's research (RO in Vancouver) is into blood tests for early cancer DNA. Not the same as tumor marker tests, but simpler and could only cost $150. I will ask him about this and if it could be used to identify early BC recurrence:

http://www.bccancer.bc.ca/about/news-stories/news/2016/new-study-aims-to-find-cancer-in-healthy-volunteers-with-a-simple-blood-test

Also, is there any research into how many women who had undergone a lumpectomy did not have a recurrence? What is the percentage of women who did not have any other cancer after her lumpectomy say for 10 years or longer?

Moderators

Black Women Added to High-Risk Group for Breast Cancer
April 27, 2018
Because black women have higher breast cancer mortality rates than white women, the American College of Radiology and the Society of Breast Imaging have recommended that black women be added to groups considered at high risk for breast cancer. Read more...

Moderators

Women With Low Muscle Mass Have Worse Survival
May 3, 2018
Women diagnosed with stage II or III breast cancer who have low muscle mass have worse survival rates than women with higher muscle mass. Read more...

Moderators

Screening Mammograms Lead to Earlier Stage at Diagnosis, Lower Need for Aggressive Treatment
May 10, 2018
A study suggests that screening mammograms every 2 years or more often are linked to breast cancers that are diagnosed at an earlier stage, which lowers the need for more aggressive treatment. Read more...

Moderators

Family History of Breast Cancer Dramatically Increases Risk of Cancer in Other Breast
May 10, 2018
A family history of breast cancer substantially increases the risk of contralateral disease in younger women. Read more...

Moderators

Financial Burden of Breast Cancer More Difficult for Black Women
May 11, 2018
Black women have more financial problems related to breast cancer than white women. Read more...

Moderators

Despite Feeling Unequipped, Many Oncologists Recommend Medical Marijuana for Patients
May 15, 2018
Most oncologists talk to their patients about medical marijuana, but don't feel they have enough knowledge. Read more...

Moderators

Writing Program Can Help Ease Body Concerns After Treatment
May 16, 2018
My Changed Body, a web-based structured writing exercise, can help ease distress related to body image and increase self-compassion among women treated for breast cancer. Read more...

Moderators

Most Women Have Multigene Genetic Testing, but Not Until After Surgery
May 17, 2018
A study has found that most women now have multigene testing after a breast cancer diagnosis, but this genetic testing is happening later in the treatment plan than testing for only BRCA1 or BRCA2 mutations. Read more...

Moderators

Genetic Testing Criteria May Miss Women With Mutations Linked to Breast Cancer
May 30, 2018
A study suggests that women who don't meet breast cancer genetic testing guidelines are just as likely to have mutations linked to breast cancer as women who meet the guidelines. This means that a large number of genetic mutations linked to breast cancer are being missed. Read more...

Moderators

Early Results Suggest 6 Months of Herceptin as Effective as Treatment for 1 Year
June 2, 2018
First results from the PERSEPHONE trial suggest that giving Herceptin for 6 months after surgery and chemotherapy offers the same decrease in recurrence risk as giving it for 1 year. Read more...

Moderators

TAILORx Results Suggest About 70% of Women With Early-Stage, Hormone-Receptor-Positive, HER2-Negative Disease Can Skip Chemotherapy
June 4, 2018
Results from the TAILORx study show that about 70% of women diagnosed with hormone-receptor-positive, HER2-negative, node-negative breast cancer do not need chemotherapy after surgery. Read more...

Larkspur

"It is the first time that a patient with late-stage breast cancer has been successfully treated by a form of immunotherapy that uses the patient's own immune cells to find and destroy cancer cells that have formed in the body."

https://www.theguardian.com/science/2018/jun/04/do...